Nuevas tecnologías genéticas: ¿Dónde están las mujeres?

Inmaculada de Melo Martín

Resumen


The new genetic technologies: Where are the women?

The propose of this paper is to show that ignoring gender issues when genetic technologies are assessed becomes problematic since such strategy can extend injustices toward woman. First, to include gender is necessary due to the medical institutions difficulties. Second, gender considerations matter when particular technologies are analyzed, like prenatal diagnosis. Such considerations are also important when moral obligations are put forward face up to the new genetic technologies, for instance, when selecting, by preimplantation diagnosis, the best babies a couple can engender.

 

Key words: Female health, genetic technologies, assisted reproduction, public health, therapeutic assesment, medical discrimination.

 


Texto completo:

PDF

Referencias


Gracias a Beatriz de Melo Martín por su ayuda con este artículo.

Ver, por ejemplo, Sandra Nicholson, “‘So you row, do you? You don’t looklike a rower.’ An account of medical students experience of sexism,” Medical Education 36(11) (2002): 1057-13; Henry Etzkowitz, Carol Kemergor y Brian Uzzi, Athena Unbound: The Advancement of Women in Science and Technology (Cambridge: Cambridge University Press, 2000); Ministerio de Trabajo y Asuntos Sociales, Instituto de la Mujer, Profesionales sanitarios/as colegiados, según tipo y sexo [en línea] [Consulta: 5 Abril, 2003]; Elaine Showalter, “Improving the position of women in medicine,” British Medical Journal 318 (7176) (1999): 71-2; Susan Sherwin, No Longer Patient (Philadelphia: Temple University Press, 1992).

Ver U.S. Census Bureau, Statistical Abstract of the United States: 2002 (Washington, US Government Printing Office, 2003) pp. 560-630. Ver también Eurostat, Women in the EU [en línea] (Luxembourg: Eurostats Press Office, 5 March, 2003) p. 3. Disponible en Portable Document Format en [Consulta: 5 Abril, 2003] y Ministerio de Trabajo y Asuntos Sociales, Instituto de la Mujer, Población ocupada, por situación profesional, tipo de jornada y sexo [en línea] [Consulta: 5 Abril, 2003].

Comisión de las Comunidades Europeas, Informe anual sobre la igualdad de oportunidades entre mujeres y hombres en la Unión Europea en 2002 [en línea] (Bruselas: COM, 2003); Disponible en PDF en [Consulta: 5 Abril, 2003]; Ministerio de Trabajo y Asuntos Sociales, Instituto de la Mujer, Mujeres en cifras, Proyecto ISOS Discriminación Salarial U.E. [en línea] Informe y tablas estadísticas [Consulta: 5 Abril, 2003]

Ver Roger Dobson, “Women are less likely than men to have rehabilitationafter a heart attack,” British Medical Journal 236 (73-80) (2003): 71; Hans Lingens, “Editor’s Introduction,” European Education 32 (4) (Winter 20002001): 3-4; L Rajmil, et al. “Gender differences in children’s hospitalization in Catalonia: another inequality?” ActaPaediatrica 88 (9) (1999): 990-7; y K. Berg-Kelly “Gender and Disease,” ActaPaediatrica 88 (9) (1999): 921-7.

Ver Ann Klassen et al., “Relations Between patients perceptions of disadvantage and discrimination and listing for kidney transplantation,” American Journal of Public Health 92 (5) (2002): 811-18; D.E. Schaubel, D.E. Stewart, H.I. Morrison, D.L. Zimmerman, J.I. Cameron, J.J. Jeffery, S.S. Fenton, “Sex inequality in kidney transplantation rates,” Archives of Internal Medicine, 160(15) (2000): 2349-54.

United Nations, Women and AIDS: UNAIDS Point of View (Geneva: UNAIDS, October 1997).

Ver, por ejemplo, Susan Sherwin, No Longer Patient (Philadelphia: Temple University Press, 1992), p.224.

Ver Rebecca Dresser, “Wanted: Single, white, male for medical research,” pp.24-29. Ver también P.R. Ferguson, “Selecting participants when testing new drugs: the implications of age and gender discrimination,” Med. Leg. J. 70 (3) (2002): 130-4; M.N. Prout, S.S. Fish, “Participation of women in clinical trials of drug therapies: a context for the controversies,” Medscape Womens Health 6 (5) (2001): 1; L.H. Glantz, “Pregnancy and informed consent to research,” J. Am. Med. Womens Assoc. 55(5) (2000):263-4; S.E. Herz, “Don’t test, do sell: legal implications of inclusion and exclusion of women in clinical drug trials,” Epilepsy 38 (Suppl. 4) (1997): S42-9

Ver referencias en nota 1.

Ver referencias en notas 1 y 2.

Ver, por ejemplo, Helen Longino, “Knowledge, bodies, and values. Reproductive technologies and their scientific context,” en Technology and the Politics of Knowledge, eds., A. Feenberg and A. Hannay (Bloomington: Indiana University Press, 1995), pp. 195-210.

Ver, por ejemplo, Helen Longino, Science as Social Knowledge (Princeton: Princeton University Press, 1992).

Ver, por ejemplo, E.M. Ettorre, Before Birth: Understanding Prenatal Screening (Aldershot, England: Ashgate, 2001) e Inmaculada de Melo Martín, “Investigación biomedica y tecnologías de reproducción,” en M.I. González, J.A. López Cerezo, J.L. López Luján (eds.) Ciencia, Tecnología y Sociedad (Madrid: Tecnos, 1996), p. 292 y Fetal Diagnosis and Therapy 8 (Suppl. 1) (1993): 1-246

Ver, por ejemplo, Rosemarie Tong, Feminist Approaches to Bioethics (Boulder, CO: Westview, 1997), ch. 9, Barbara Katz Rothman, Tentative Pregnancy (New York: W.W. Norton, 1993)

Ver, por ejemplo, L.D. Ray, “Parenting and childhood chronicity: making visible the invisible work,” J. Pediatr. Nurs. 17 (6) (2002): 424-38; y Alan Gartner, et al., Supporting Families with a Child with a Disability: An International Outlook (Baltimore, MD.: Paul H. Brookes, 1991).

Ver, por ejemplo, Walter Glannon, Genes and Future People (Boulder, CO: Westview, 2001), ch. 2; Rosamond Rhodes, “Genetic links, family ties and social bonds: Rights and responsibilities in the face of genetic knowledge,” Journal of Medicine and Philosophy 23 (1) (1998): 10–30, y Laura Purdy, Reproducing Persons (Ithaca, NY: Cornell University Press, 1996) pp. 39-49.

Julián Savulescu. “Procreative beneficence: why we should select the bestchildren,” Bioethics 15 (5) (2001): 413-426.

Julian Savulescu, “Procreative beneficence: why we should select the bestchildren,” Bioethics 15 (5) (2001): 413-426.

Inmaculada de Melo-Martín, “On our obligation to select the best children,”Bioethics, en prensa.

Ver, por ejemplo, J. Botkin, “Ethical issues and practical problems in preimplantation genetic diagnosis,” Journal of Law, Medicine & Ethics 26 (1) (1998): 17-28.

Ver, por ejemplo, Ascensión Cambrón, (ed.) Reproducción asistida: promesas, normas y realidad (Madrid: Trotta, 2002); F.J. Ramiro Técnicas de Asistencia a la Reproducción Humana: valoración ética (Bilbao: Grafite, 2000), Elisabeth Hildt y Dietmar Mieth, In Vitro Fertilization in the 1990’s (Aldershot, UK: Ashgate, 1998).

Ver, por ejemplo, Inmaculada de Melo-Martín, Making Babies (Dordrecht: Kluwer, 1998).

Op. cit. ch. 4.

Ver, por ejemplo, Alison Venn, “Risk of cancer after use of fertility drugs within-vitro fertilization,” Lancet 354(9190) (1999):1586-90; R. E. Bristow and B. Y. Karlan “The risk of ovarian cancer after treatment for infertility,” Curr. Opin. Obstet. Gynecol. 8 (1) (1996): 32-7; y A. Shushan et al., “Human menopausal gonadotropin and the risk of epithelial ovarian cancer,” Fertility and Sterility 65 (1) (1996): 13-8; J. Jarrel, J. Seidel, and P. Bigelow, “Adverse health effects of drugs used for ovulation induction,” en Royal Commission on New Reproductive Technologies, New Reproductive Technologies and the Health Care System. The Case for Evidence-Based Medicine (Ottawa: Canada Communications Group) pp. 453-549; P. Stephenson “Ovulation induction during treatment of infertility: an assessment of the risks,” en P. Stephenson and M. G. Wagner, eds. Tough Choices. (Philadelphia: Temple University Press,) pp.97121; R. E. Bristow and B. Y. Karlan, “The risk of ovarian cancer after treatment for infertility,” Curr. Opin. Obstet. Gynecol. 8 (1996): 32-7.

Ver, por ejemplo, J.V. Jr Lacey et al., “Menopausal hormone replacement therapy and risk of ovarian cancer,” JAMA 288(3) (2002): 334-41; C. F. Schairer et al., “Menopausal estrogen and estrogen-progestin replacement therapy and breast cancer risk,” JAMA 283(4) (2000): 485-91; F. Berrino et al, “Serum sex hormone levels after menopause and subsequent breast cancer,” J. Natl. Cancer Inst. 88 (5) (1996): 291-6.

Ver, por ejemplo, S. Y. Mitchell et al., “Ovarian hyperstimulation syndrome associated with clomiphene citrate,” West Indian Med. J. 50(3) (2001): 227-9; A. Delvigne, S. Rozenberg, “Preventive attitude of physicians to avoid OHSS in IVF patients,” Hum. Reprod. 16(12) (2001): 2491-5; B. McElhinney, N. McClure, “Ovarian hyperstimulation syndrome,” Baillieres Best Pract. Res. Clin. Obstet. Gynaecol. 14(1) (2000): 103-22; J.G. Schenker, “Clinical aspects of ovarian hyperstimulation syndrome,” Eur. J. Obstet. Gynecol. Reprod. Biol. 85(1) (1999):13-20; y H.S. Jacobs, R. Agrawal, “Complications of ovarian stimulation,” Baillieres Clin. Obstet. Gynaecol. 12(4) (1998):565-79.

Ver, por ejemplo, Inmaculada de Melo-Martín, Making Babies (Dordrecht: Kluwer, 1998), ch. 4 y R. Rowland, Living Laboratories, (Bloomington, IN: Indiana University Press, 1992) pp. 25-30.


Enlaces refback

  • No hay ningún enlace refback.


Revista semestral editada por el Centro de Estudios Filosóficos, Políticos
y Sociales Vicente Lombardo Toledano de la Secretaría de Educación Pública,
la Universidad Autónoma Metropolitana-Iztapalapa y Edicions UIB de la Universitat de les Illes Balears.

Lombardo Toledano 51, Col. Ex-Hda. Guadalupe Chimalistac,
Del. Alvaro Obregón, C.P. 01050, México, D.F.
Tels. (5255) 5661-4679 y 5661-4987
Fax: (5255) 5661-1787